Catalysts · MRK · CIK 310158 · page 4 of 4

MRK catalysts and FDA events, page 4.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on MRK PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
June 3, 2025KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
Jun 2025Month disclosedLIPFENDRA (enlicitide)MRKTopline readoutwith hyperlipidemiaPositiveSEC Form 10-Q
May 26, 2025MK-6482MRKPDUFA date—ScheduledSEC Form 10-Q
May 22, 2025KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
May 21, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completionColorectal CancerCompletedClinicalTrials.gov
May 14, 2025WELIREG® (belzutifan)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
May 8, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completionMetastatic Esophageal Squamous Cell CarcinomaWithdrawnClinicalTrials.gov
April 24, 2025—MRKEarnings—CompletedSEC 8-K Exhibit 99.1
April 21, 2025KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
April 15, 2025WELIREG® (belzutifan)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
March 19, 2025KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
February 4, 2025—MRKEarnings—CompletedSEC 8-K Exhibit 99.1
January 28, 2025KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
Jan 2025Month disclosedWINREVAIR (sotatercept)MRKInterim readout—PositiveSEC Form 10-K
December 12, 2024Bridion (sugammadex sodium)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 11, 2024KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
Nov 2024Month disclosedWINREVAIR (sotatercept)MRKTopline readout—PositiveSEC Form 10-K
September 26, 2024KEYTRUDA® (pembrolizumab)MRKAdvisory committee—CompletedFDA advisory committee calendar
September 17, 2024KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
August 30, 2024Prevymis (letermovir)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
August 30, 2024Prevymis (letermovir)MRKFDA approval—ApprovedopenFDA Drugs@FDA
August 7, 2024KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 26, 2024Ohtuvayre (ensifentrine)MRKFDA approvalTo treat chronic obstructive pulmonary diseaseApprovedFDA Novel Drug Approvals
June 7, 2024KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
March 26, 2024Winrevair (sotatercept-csrk)MRKFDA approvalTo treat pulmonary arterial hypertensionApprovedFDA Novel Drug Approvals
Mar 2024Month disclosedgenericMRKFDA approval—ApprovedSEC Form 10-K
January 25, 2024KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 12, 2024KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 15, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 14, 2023WELIREG® (belzutifan)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
November 7, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
October 23, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
October 12, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
September 14, 2023Temodar (temozolomide)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
August 14, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
August 2, 2023Prevymis (letermovir)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 5, 2023Prevymis (letermovir)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
May 26, 2023Zinplava (bezlotoxumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
March 28, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 26, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
Jan 2023Month disclosedJanuvia (sitagliptin)MRKFDA approval—ApprovedSEC Form 10-Q
December 16, 2022KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
May 20, 2022KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
May 2, 2022Fosaprepitant Dimeglumine (fosaprepitant dimeglumine)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
March 21, 2022KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
February 4, 2022KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 27, 2022Delstrigo (doravirine; lamivudine; tenofovir disoproxil fumarate)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 27, 2022Pifeltro (doravirine)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 17, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 9, 2021Zepatier (elbasvir; grazoprevir)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 3, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
November 17, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
October 13, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
September 17, 2021Steglujan (ertugliflozin; sitagliptin phosphate)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
September 17, 2021Segluromet (ertugliflozin; metformin hydrochloride)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
September 17, 2021Steglatro (ertugliflozin)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
August 31, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
August 13, 2021WELIREG® (belzutifan)MRKFDA approval—ApprovedopenFDA Drugs@FDA
August 10, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
July 21, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
July 1, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 25, 2021Bridion (sugammadex sodium)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 17, 2021Noxafil (posaconazole)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
May 31, 2021Noxafil (posaconazole)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
May 31, 2021Noxafil (posaconazole)MRKFDA approval—ApprovedopenFDA Drugs@FDA
May 5, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
March 16, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 22, 2021Bridion (sugammadex sodium)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 19, 2021Verquvo (vericiguat)MRKFDA approval—ApprovedopenFDA Drugs@FDA
December 4, 2020Januvia (sitagliptin)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 4, 2020Janumet (metformin hydrochloride; sitagliptin phosphate)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
November 13, 2020KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
October 14, 2020KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
October 2, 2020KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
July 14, 2020Isentress (raltegravir potassium)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 29, 2020KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 16, 2020KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 9, 2020Bridion (sugammadex sodium)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 4, 2020Recarbrio (cilastatin sodium; imipenem; relebactam)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
April 28, 2020KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 29, 2020Belsomra (suvorexant)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 8, 2020KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
July 16, 2019Recarbrio (cilastatin sodium; imipenem; relebactam)MRKFDA approval—ApprovedopenFDA Drugs@FDA
August 30, 2018Delstrigo (doravirine; lamivudine; tenofovir disoproxil fumarate)MRKFDA approval—ApprovedopenFDA Drugs@FDA
August 30, 2018Pifeltro (doravirine)MRKFDA approval—ApprovedopenFDA Drugs@FDA
December 19, 2017Steglujan (ertugliflozin; sitagliptin phosphate)MRKFDA approval—ApprovedopenFDA Drugs@FDA
December 19, 2017Segluromet (ertugliflozin; metformin hydrochloride)MRKFDA approval—ApprovedopenFDA Drugs@FDA
December 19, 2017Steglatro (ertugliflozin)MRKFDA approval—ApprovedopenFDA Drugs@FDA
November 8, 2017Prevymis (letermovir)MRKFDA approval—ApprovedopenFDA Drugs@FDA
October 21, 2016Zinplava (bezlotoxumab)MRKFDA approval—ApprovedopenFDA Drugs@FDA
January 28, 2016Zepatier (elbasvir; grazoprevir)MRKFDA approval—ApprovedopenFDA Drugs@FDA
June 28, 2013Belsomra (suvorexant)MRKComplete Response Letter—CRL issuedFDA Complete Response Letters
Every catalyst is quoted from MRK’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.